Log In
Print this Print this

doxepin (Silenor)

Also known as: SO-101

  Manage Alerts
Collapse Summary General Information
Company Pernix Therapeutics Holdings Inc.
DescriptionLow-dose tricyclic doxepin
Molecular Target Histamine H1 receptor (HRH1) ; Histamine receptor
Mechanism of ActionHistamine H1 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInsomnia
Indication DetailsTreat insomnia; Treat insomnia characterized by nocturnal awakenings and/or early morning awakenings; Treat insomnia in elderly patients; Treat primary chronic insomnia; Treat primary sleep maintenance insomnia; Treat transient insomnia
Regulatory Designation
Partner CJ Group; Endo International plc; Procter & Gamble Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today